-
2024-512119-34-00
4
2022-06-20
MSI-H/dMMR metastatic colorectal cancer
-
2024-518223-29-00
4
2020-03-10
Advanced or metastatic untreated EGFR mutation positive NSCLC
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2023-509180-24-00
4
2026-02-12
vulvar cancer
-
2024-519798-20-00
4
2026-01-15
pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
-
2025-522786-29-00
4
2026-01-07
Spastic Cerebral Palsy
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2024-517866-40-00
4
2025-09-29
Moderate-to-severe Asthma
-
2024-517896-19-00
3
2025-09-29
Patients with Rheumatoid Arthritis (RA) who, despite treatment with st
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2023-510356-23-00
1
2025-07-18
Locally advanced or metastatic unresectable colorectal
cancer (CRC)
-
2024-517789-41-00
6
2025-07-04
metastatic or locally advanced renal cell carcinoma
-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2024-519248-34-00
4
2025-06-17
Cervical Dystonia
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
-
2024-513959-33-00
4
2025-05-13
Asthma
-
2024-516347-41-00
4
2025-04-29
VEXAS Syndrome
-
2023-506206-38-00
4
2025-04-09
Diffuse Large B-cells non-Hodgkin Lymphoma